NCT00141882CompletedPhase 3
Memantine in Patients With Chronic Glaucoma
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Allergan
- Enrollment
- 1,119
- Primary Endpoint
- Progression of glaucoma
Study Overview
Brief Summary
Randomized double-masked clinical trial of memantine in patients with glaucoma
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Glaucoma damage on examination of visual field and optic disc
- •Good visual acuity (with glasses if needed)
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Progression of glaucoma
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 3
Memantine in Patients With Chronic GlaucomaOpen-Angle GlaucomaNCT00168350Allergan1,179
Recruiting
Not Applicable
The Glaucoma Nicotinamide TrialGlaucomaNCT05275738Umeå University660
Completed
Phase 3
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)GlaucomaOcular HypertensionNCT00108017Merck Sharp & Dohme LLC330
Completed
Phase 2
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressurePrimary Open Angle GlaucomaOcular HypertensionNCT06144918Skye Bioscience, Inc.56
Completed
Phase 3
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual DisturbancesMesopic VisionNight Vision LossNCT06349759Ocuphire Pharma, Inc.200